
Medicalgorithmics is a medical technology company specialized in AI-powered and noninvasive solutions for cardiac arrhythmia. Over the past 15 years, we have transformed into a global provider of cutting-edge solutions that help improve the health of patients around the world. We have put science and innovation at the heart of our work. We are closely cooperating with healthcare professionals to reduce costs, streamline clinical workflows and most importantly improve the quality of patient care. We are striving to design AI algorithms that can accurately detect and diagnose diseases at an early stage, increasing the chances of a successful treatment. Our innovative portfolio spans across software, artificial intelligence and cloud based solutions for healthcare systems, physicians and medical technology companies. Our flagship products include PocketECG system, FDA-approved TechBot and DeepRhythm software platforms for cardiac arrhythmia. We invented noninvasive AI-powered VCAST (Virtual Cardiac Stress Test) technology, which we believe can revolutionize the diagnosis and treatment of coronary artery disease in the years ahead. Medicalgorithmics has been listed on the Warsaw Stock Exchange since 2014.
We're tracking Medicalgorithmics S.A.'s market expansion
New Marketing & PR activity — 34 fresh signals just appeared.
How Medicalgorithmics S.A.'s international expansion compares to its competitors
Bars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
Medicalgorithmics S.A.You | 0 | 0 | — | 0 | 0 |
Quality Assurance and Regulatory Affairs Specialist (QMS & Audits)
View postingWarsaw, Mazowieckie, Poland · 4mo ago
Connect your clinical team with cloud-based coronary diagnostics:
EndedConnect your clinical team with cloud-based coronary diagnostics:
EndedConnect your clinical team with cloud-based coronary diagnostics:
EndedEnergy stocks rise on dividend news and results. CCC falls on poor earnings. Rainbow Tours, Newag, and Medicalgorithmics gain on positive developments.
Trump announces two-week Iran ceasefire, oil drops 15.9%. Rex Concepts plans GPW IPO for 560M PLN. Kęty prepares acquisitions, Biofund eyes Pure Biologics stake.
Medicalgorithmics estimates Q3 2025 consolidated sales revenue at 7.2 million PLN, up 38% year-over-year. US sales increased 76% to 2.2 million PLN. ECG analysis sessions reached 96,617.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Medicalgorithmics S.A.'s business, markets, and growth signals.

© 2026 Pubrio. All rights reserved.